Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 7;37(1):46.
doi: 10.1186/s43046-025-00292-0.

Neoadjuvant chemoradiation and surgical excision versus definitive radiotherapy for locally advanced cervix uteri carcinoma: in terms of early and late complications and locoregional recurrence

Hisham Khalifa  1 , Mohamed Ayaty  2 , Reham Oreaba  3 , Reem Emad  3 , Mohamed Salama  3 , Khaled Elsebahy  3 , Wael A Wahab Ghoniem  3
Affiliations

Neoadjuvant chemoradiation and surgical excision versus definitive radiotherapy for locally advanced cervix uteri carcinoma: in terms of early and late complications and locoregional recurrence

Hisham Khalifa et al. J Egypt Natl Canc Inst. .

Abstract

Objectives: Following external beam radiation therapy (EBRT) with concurrent chemotherapy, we analyzed the benefits of surgical resection for locally advanced cervical carcinoma in terms of the frequency and severity of complications and disease-free survival, including cases of adjuvant hysterectomy after failure of resolution post-brachytherapy.

Patient and methods: Retrospective analysis was utilized to determine the eligibility of 145 cases treated at the National Cancer Institute between January 2015 and June 2021. Of those, 17 patients did not match the requirements, and 8 patients declined to take part in the study. Depending on the major treatment technique, 120 FIGO stage IB3-FIGO stage IVA cervical cancer patients were split into two equal groups of 60 patients each. Sixty patients (50%) received neo-adjuvant EBRT and concurrent platinum-based chemotherapy followed by hysterectomy (group A) and 60 (50%) received definitive radiotherapy only (group B).

Results: The age at diagnosis of patients was similar, with a mean of 52.5 (range 34-77) and 53.4 (range 25 81) years in group A and group B, respectively (P = 0.675). Majority of the cases in both groups were pathologically squamous cell carcinomas (88.3% in group A and 83.3% in group B) and of grade II differentiation (73.7% in group A and 71.2% in group B). Majority of cases in both groups being FIGO stage II (45% in group A and 40% in group B) and FIGO stage III (40% in group A and 43.3% in group B). Only 17 patients (28.3%) in group A had postoperative complications, while 37 patients (61.7%) in group B suffered from post-treatment complications (P value < 0.001). In group B, 14 patients (23.3%) failed to show complete remission of the disease after completion of treatment, with a mean residual disease of 4.3 cm in diameter (range 2-6 cm), either local or nodal. Salvage hysterectomy post-definitive radiotherapy was done for 8 patients with residual disease (13.3%). In group A, 48 patients had no recurrence during follow-up (80%), while 11 of the patients had either locoregional or metastatic recurrences, or both (18.3%). DFS was comparable between both groups (P = 0.493), excluding 23.3% of group B where failure of complete remission of the disease after completion of treatment barred the patients from the disease-free calculations. The 1-year DFS was 88.1% in group A and 82.6% in group B, while the 3-year DFS was 74.1% in group A and 70.1% in group B.

Conclusion: There was no difference in disease-free survival or the incidence of locoregional and metastatic recurrence between patients with cervical cancer who had surgery and those who received brachytherapy following EBRT and concomitant chemotherapy. In almost 50% of cases, the surgical patients showed full pathological recovery.

Keywords: Adjuvant hysterectomy; Cervix; Definitive radiotherapy; Neoadjuvant chemoradiation.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study was approved by Cairo University’s National Cancer Institute Ethics Committee. At the time of their admission, every participant consented in writing to the use of their data for medical study. The study was conducted in accordance with the Helsinki Declaration. The patient gave written, informed consent for the original article to be published. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Serarslan A, Meydan D, Yildiz RE. Radical radiotherapy of locally advanced cervix uteri carcinoma. Archives of Cancer Biology and Therapy. 2021;2(1):8–14.
    1. Lu W, Lu C, Yu Z, Gao L. Chemoradiotherapy alone vs. chemoradiotherapy and hysterectomy for locally advanced cervical cancer: a systematic review and updated meta-analysis. Oncol Lett. 2021;21(2):1–1.
    1. Li W, Liu P, Zhao W, Yin Z, Lin Z, Bin X, Lang J, Chen C. Effects of preoperative radiotherapy or chemoradiotherapy on postoperative pathological outcome of cervical cancer–from the large database of 46,313 cases of cervical cancer in China. Eur J Surg Oncol. 2020;46(1):148–54. - DOI - PubMed
    1. Federico A, Anchora LP, Gallotta V, Fanfani F, Cosentino F, Turco LC, Bizzarri N, Legge F, Teodorico E, Macchia G, Valentini V. Clinical impact of pathologic residual tumor in locally advanced cervical cancer patients managed by chemoradiotherapy followed by radical surgery: a large, multicenter, retrospective study. Ann Surg Oncol. 2022;29(8):4806–14. - DOI - PubMed - PMC
    1. Ferrandina G, Legge F, Fagotti A, Fanfani F, Distefano M, Morganti A, Cellini N, Scambia G. Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol Oncol. 2007;107(1):S127–32. - DOI - PubMed

MeSH terms